{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:27:56Z","timestamp":1778758076848,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06900-w","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:16:49Z","timestamp":1776413809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health-related quality of life of patients with acute myeloid leukemia and myelodysplastic syndromes\/neoplasms treated with decitabine: a systematic literature review"],"prefix":"10.1007","volume":"105","author":[{"given":"Laura","family":"Cannella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Venditti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Puglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Luppi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Efficace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"6900_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM et al (2019) Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev 36:70\u201387","journal-title":"Blood Rev"},{"key":"6900_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.blre.2018.09.001","volume":"34","author":"AM Zeidan","year":"2019","unstructured":"Zeidan AM et al (2019) Epidemiology of myelodysplastic syndromes: why characterizing the Beast is a prerequisite to taming it. Blood Rev 34:1\u201315","journal-title":"Blood Rev"},{"key":"6900_CR3","doi-asserted-by":"publisher","first-page":"204062072312054","DOI":"10.1177\/20406207231205429","volume":"14","author":"R Briski","year":"2023","unstructured":"Briski R et al (2023) The history of oral decitabine\/cedazuridine and its potential role in acute myeloid leukemia. Ther Adv Hematol 14:20406207231205429","journal-title":"Ther Adv Hematol"},{"issue":"11","key":"6900_CR4","doi-asserted-by":"publisher","first-page":"e879","DOI":"10.1016\/S2352-3026(23)00273-9","volume":"10","author":"M L\u00fcbbert","year":"2023","unstructured":"L\u00fcbbert M et al (2023) 10-day decitabine versus 3\u2008+\u20087 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. Lancet Haematol 10(11):e879\u2013e889","journal-title":"Lancet Haematol"},{"issue":"11","key":"6900_CR5","doi-asserted-by":"publisher","first-page":"e830","DOI":"10.1016\/S2352-3026(24)00241-2","volume":"11","author":"D Russo","year":"2024","unstructured":"Russo D et al (2024) Venetoclax plus decitabine as a Bridge to allogeneic Haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial. Lancet Haematol 11(11):e830\u2013e838","journal-title":"Lancet Haematol"},{"issue":"22","key":"6900_CR6","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1182\/blood.2024027217","volume":"145","author":"J Lu","year":"2025","unstructured":"Lu J et al (2025) Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML. Blood 145(22):2645\u20132655","journal-title":"Blood"},{"issue":"9","key":"6900_CR7","doi-asserted-by":"publisher","first-page":"e705","DOI":"10.1016\/S2352-3026(25)00172-3","volume":"12","author":"M Robin","year":"2025","unstructured":"Robin M et al (2025) Oral decitabine and Cedazuridine maintenance after Haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial. Lancet Haematol 12(9):e705\u2013e716","journal-title":"Lancet Haematol"},{"issue":"8","key":"6900_CR8","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1182\/bloodadvances.2020002929","volume":"5","author":"AA Patel","year":"2021","unstructured":"Patel AA et al (2021) Cedazuridine\/decitabine: from preclinical to clinical development in myeloid malignancies. Blood Adv 5(8):2264\u20132271","journal-title":"Blood Adv"},{"issue":"1","key":"6900_CR9","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","volume":"11","author":"G Garcia-Manero","year":"2024","unstructured":"Garcia-Manero G et al (2024) Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol 11(1):e15\u2013e26","journal-title":"Lancet Haematol"},{"issue":"5","key":"6900_CR10","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/bjh.19741","volume":"205","author":"K Geissler","year":"2024","unstructured":"Geissler K et al (2024) Oral decitabine\/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study. Br J Haematol 205(5):1734\u20131745","journal-title":"Br J Haematol"},{"issue":"14","key":"6900_CR11","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on Imatinib. J Clin Oncol 28(14):2381\u20132388","journal-title":"J Clin Oncol"},{"issue":"1","key":"6900_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/asheducation-2016.1.170","volume":"2016","author":"F Efficace","year":"2016","unstructured":"Efficace F, Cannella L (2016) The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. Hematol Am Soc Hematol Educ Program 2016(1):170\u2013179","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"6900_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/cncr.35021","volume":"130","author":"F Efficace","year":"2024","unstructured":"Efficace F et al (2024) Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia. Cancer 130(2):287\u2013299","journal-title":"Cancer"},{"issue":"21","key":"6900_CR14","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1182\/blood.V118.21.1026.1026","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace F et al (2011) Investigating personal and treatment related factors associated with adherence behavior in patients with chronic myeloid leukemia receiving long term Imatinib therapy. Blood 118(21):1026","journal-title":"Blood"},{"issue":"4","key":"6900_CR15","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/S2352-3026(19)30030-4","volume":"6","author":"MR Savona","year":"2019","unstructured":"Savona MR et al (2019) An oral fixed-dose combination of decitabine and Cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol 6(4):e194\u2013e203","journal-title":"Lancet Haematol"},{"issue":"4","key":"6900_CR16","doi-asserted-by":"publisher","first-page":"e276","DOI":"10.1016\/S2352-3026(24)00033-4","volume":"11","author":"A Bazinet","year":"2024","unstructured":"Bazinet A et al (2024) Oral decitabine and Cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol 11(4):e276\u2013e286","journal-title":"Lancet Haematol"},{"issue":"1","key":"6900_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","volume":"14","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H et al (2024) Current status and research directions in acute myeloid leukemia. Blood Cancer J 14(1):163","journal-title":"Blood Cancer J"},{"issue":"1","key":"6900_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41408-025-01346-1","volume":"15","author":"N Gangat","year":"2025","unstructured":"Gangat N, Dinardo CD (2025) Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms. Blood Cancer J 15(1):139","journal-title":"Blood Cancer J"},{"issue":"24","key":"6900_CR19","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1200\/JCO-25-00640","volume":"43","author":"CD DiNardo","year":"2025","unstructured":"DiNardo CD et al (2025) Outcomes of frontline triplet regimens with a hypomethylating Agent, Venetoclax, and isocitrate dehydrogenase inhibitor for intensive Chemotherapy-Ineligible patients with isocitrate dehydrogenase-Mutated AML. J Clin Oncol 43(24):2692\u20132699","journal-title":"J Clin Oncol"},{"key":"6900_CR20","doi-asserted-by":"crossref","unstructured":"Kropf PL et al (2025) A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML. Blood Neoplasia, 2(2)","DOI":"10.1016\/j.bneo.2025.100071"},{"key":"6900_CR21","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"3","key":"6900_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1200\/JCO.19.01053","volume":"38","author":"M L\u00fcbbert","year":"2020","unstructured":"L\u00fcbbert M et al (2020) Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 \u00d7 2, Phase II Trial. J Clin Oncol 38(3):257\u2013270","journal-title":"J Clin Oncol"},{"issue":"1","key":"6900_CR23","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12885-015-1432-5","volume":"15","author":"O Grishina","year":"2015","unstructured":"Grishina O et al (2015) DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients\u2009>\u200960 years with acute myeloid leukemia who are ineligible for induction chemotherapy. BMC Cancer 15(1):430","journal-title":"BMC Cancer"},{"issue":"12","key":"6900_CR24","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1182\/bloodadvances.2021006872","volume":"6","author":"EK Ritchie","year":"2022","unstructured":"Ritchie EK et al (2022) Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101. Blood Adv 6(12):3812\u20133820","journal-title":"Blood Adv"},{"issue":"24","key":"6900_CR25","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1182\/bloodadvances.2018023689","volume":"2","author":"GJ Roboz","year":"2018","unstructured":"Roboz GJ et al (2018) Randomized trial of 10 days of decitabine\u2009\u00b1\u2009bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Adv 2(24):3608\u20133617","journal-title":"Blood Adv"},{"issue":"7","key":"6900_CR26","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.jgo.2021.09.007","volume":"13","author":"JD Peipert","year":"2022","unstructured":"Peipert JD et al (2022) Patient-reported outcomes predict overall survival in older patients with acute myeloid leukemia. J Geriatr Oncol 13(7):935\u2013939","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"6900_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41375-020-0773-5","volume":"35","author":"P Montesinos","year":"2021","unstructured":"Montesinos P et al (2021) Safety and efficacy of Talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2\/3 study. Leukemia 35(1):62\u201374","journal-title":"Leukemia"},{"issue":"3","key":"6900_CR28","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/ajh.27212","volume":"99","author":"A Im","year":"2024","unstructured":"Im A et al (2024) Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients. Am J Hematol 99(3):380\u2013386","journal-title":"Am J Hematol"},{"issue":"5","key":"6900_CR29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1182\/blood.2023023625","volume":"144","author":"F Efficace","year":"2024","unstructured":"Efficace F et al (2024) Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial. Blood 144(5):541\u2013551","journal-title":"Blood"},{"issue":"8","key":"6900_CR30","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H et al (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106(8):1794\u20131803","journal-title":"Cancer"},{"issue":"15","key":"6900_CR31","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"M L\u00fcbbert","year":"2011","unstructured":"L\u00fcbbert M et al (2011) Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European organisation for research and treatment of cancer leukemia group and the German MDS study group. J Clin Oncol 29(15):1987\u20131996","journal-title":"J Clin Oncol"},{"issue":"3","key":"6900_CR32","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/j.clml.2021.09.009","volume":"22","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM et al (2022) Injectable hypomethylating agents for management of myelodysplastic syndromes: patients\u2019 perspectives on treatment. Clin Lymphoma Myeloma Leuk 22(3):e185\u2013e198","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"6900_CR33","doi-asserted-by":"publisher","first-page":"e853","DOI":"10.1016\/j.clml.2022.04.023","volume":"22","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM et al (2022) Patient preferences for Benefits, Risks, and administration route of hypomethylating agents in myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 22(9):e853\u2013e866","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6900_CR34","doi-asserted-by":"publisher","first-page":"204062072412573","DOI":"10.1177\/20406207241257313","volume":"15","author":"AM Zeidan","year":"2024","unstructured":"Zeidan AM et al (2024) Patients\u2019 perspectives on oral decitabine\/cedazuridine for the treatment of myelodysplastic syndromes\/neoplasms. Ther Adv Hematol 15:20406207241257313","journal-title":"Ther Adv Hematol"},{"issue":"12","key":"6900_CR35","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"issue":"1","key":"6900_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/bloodadvances.2021004568","volume":"6","author":"I Stojkov","year":"2022","unstructured":"Stojkov I et al (2022) Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists. Blood Adv 6(1):1\u201312","journal-title":"Blood Adv"},{"issue":"16","key":"6900_CR37","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1182\/bloodadvances.2020002314","volume":"4","author":"K Stojkov","year":"2020","unstructured":"Stojkov K et al (2020) Guideline-based indicators for adult patients with myelodysplastic syndromes. Blood Adv 4(16):4029\u20134044","journal-title":"Blood Adv"},{"issue":"21","key":"6900_CR38","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H et al (2024) Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood 144(21):2169\u20132173","journal-title":"Blood"},{"issue":"7","key":"6900_CR39","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1001\/jamaoncol.2018.0677","volume":"4","author":"ML Sorror","year":"2018","unstructured":"Sorror ML, Storer BE, Estey EH (2018) Incorporating physical function and cognition into mortality risk assessment for acute myeloid Leukemia-Reply. JAMA Oncol 4(7):1014\u20131015","journal-title":"JAMA Oncol"},{"issue":"2","key":"6900_CR40","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/annonc\/mdt557","volume":"25","author":"F Efficace","year":"2014","unstructured":"Efficace F et al (2014) Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes. Ann Oncol 25(2):447\u2013454","journal-title":"Ann Oncol"},{"issue":"15","key":"6900_CR41","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.21.02810","volume":"40","author":"A Gupta","year":"2022","unstructured":"Gupta A, Eisenhauer EA, Booth CM (2022) The time toxicity of cancer treatment. J Clin Oncol 40(15):1611\u20131615","journal-title":"J Clin Oncol"},{"issue":"5","key":"6900_CR42","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.leukres.2015.03.006","volume":"39","author":"M Cabrero","year":"2015","unstructured":"Cabrero M et al (2015) Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. Leuk Res 39(5):520\u2013524","journal-title":"Leuk Res"},{"issue":"12","key":"6900_CR43","doi-asserted-by":"publisher","first-page":"100610","DOI":"10.1016\/j.apjon.2024.100610","volume":"11","author":"C Nwozichi","year":"2024","unstructured":"Nwozichi C et al (2024) Time toxicity in cancer care: A concept analysis using walker and avant\u2019s method. Asia Pac J Oncol Nurs 11(12):100610","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"11","key":"6900_CR44","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamadermatol.2023.3179","volume":"159","author":"SB Bateni","year":"2023","unstructured":"Bateni SB et al (2023) Changes in health care Costs, Survival, and time toxicity in the era of immunotherapy and targeted systemic therapy for melanoma. JAMA Dermatology 159(11):1195\u20131204","journal-title":"JAMA Dermatology"},{"issue":"7","key":"6900_CR45","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1182\/blood-2017-03-737403","volume":"130","author":"F Efficace","year":"2017","unstructured":"Efficace F, Gaidano G, Lo-Coco F (2017) Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice? Blood 130(7):859\u2013866","journal-title":"Blood"},{"issue":"3","key":"6900_CR46","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/17474086.2025.2469719","volume":"18","author":"S Molica","year":"2025","unstructured":"Molica S (2025) Navigating the gap between guidelines and practical challenges in selecting first-line therapy for chronic lymphocytic leukemia. Expert Rev Hematol 18(3):195\u2013200","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"6900_CR47","doi-asserted-by":"publisher","first-page":"e966","DOI":"10.1097\/HS9.0000000000000966","volume":"7","author":"RA Mesa","year":"2023","unstructured":"Mesa RA et al (2023) Patient-reported outcomes and quality of life in anemic and symptomatic patients with myelofibrosis: results from the MOMENTUM study. Hemasphere 7(11):e966","journal-title":"Hemasphere"},{"issue":"9 Suppl 5","key":"6900_CR48","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.2146\/ajhp070035","volume":"64","author":"J Aisner","year":"2007","unstructured":"Aisner J (2007) Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm 64(9 Suppl 5):S4\u20137","journal-title":"Am J Health Syst Pharm"},{"issue":"10","key":"6900_CR49","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1200\/JCO.21.02529","volume":"40","author":"LA Levit","year":"2022","unstructured":"Levit LA et al (2022) Call to action for improving oral anticancer agent adherence. J Clin Oncol 40(10):1036\u20131040","journal-title":"J Clin Oncol"},{"issue":"3","key":"6900_CR50","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3324\/haematol.2012.082511","volume":"99","author":"L Noens","year":"2014","unstructured":"Noens L et al (2014) Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. Haematologica 99(3):437\u2013447","journal-title":"Haematologica"},{"issue":"22","key":"6900_CR51","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L et al (2009) Prevalence, determinants, and outcomes of nonadherence to Imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113(22):5401\u20135411","journal-title":"Blood"},{"issue":"7","key":"6900_CR52","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.leukres.2012.02.032","volume":"36","author":"M Breccia","year":"2012","unstructured":"Breccia M, Efficace F, Alimena G (2012) Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Leuk Res 36(7):804\u2013805","journal-title":"Leuk Res"},{"issue":"5","key":"6900_CR53","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","volume":"35","author":"L Eliasson","year":"2011","unstructured":"Eliasson L et al (2011) Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug Imatinib as prescribed. Leuk Res 35(5):626\u2013630","journal-title":"Leuk Res"},{"issue":"1","key":"6900_CR54","first-page":"56","volume":"59","author":"K Ruddy","year":"2009","unstructured":"Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59(1):56\u201366","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"6900_CR55","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3324\/haematol.2013.093724","volume":"99","author":"F Efficace","year":"2014","unstructured":"Efficace F et al (2014) Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica 99(4):788\u2013793","journal-title":"Haematologica"},{"issue":"5","key":"6900_CR56","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrclinonc.2015.222","volume":"13","author":"M Di Maio","year":"2016","unstructured":"Di Maio M et al (2016) Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat Rev Clin Oncol 13(5):319\u2013325","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"6900_CR57","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1080\/0284186X.2020.1717604","volume":"59","author":"CL Riis","year":"2020","unstructured":"Riis CL et al (2020) Satisfaction with care and adherence to treatment when using patient reported outcomes to individualize follow-up care for women with early breast cancer - a pilot randomized controlled trial. Acta Oncol 59(4):444\u2013452","journal-title":"Acta Oncol"},{"issue":"4","key":"6900_CR58","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41408-022-00668-8","volume":"12","author":"KW Pratz","year":"2022","unstructured":"Pratz KW et al (2022) Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood Cancer J 12(4):71","journal-title":"Blood Cancer J"},{"issue":"16","key":"6900_CR59","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P et al (2022) Ivosidenib and Azacitidine in IDH1-Mutated acute myeloid leukemia. N Engl J Med 386(16):1519\u20131531","journal-title":"N Engl J Med"},{"issue":"1","key":"6900_CR60","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/17474086.2025.2570333","volume":"19","author":"P Niscola","year":"2026","unstructured":"Niscola P (2026) Evaluating quality-of-life outcomes during decitabine therapy in older adults with acute myeloid leukemia: overview of reported studies and assessment instruments. Expert Rev Hematol 19(1):5\u20138","journal-title":"Expert Rev Hematol"},{"key":"6900_CR61","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2147\/CEOR.S495401","volume":"17","author":"A Di Costanzo","year":"2025","unstructured":"Di Costanzo A et al (2025) Economic burden of intravenous decitabine administration in patients affected by acute myeloid leukemia ineligible for induction chemotherapy and impact of oral formulation introduction: A Micro-Costing study in Italy. Clinicoecon Outcomes Res 17:171\u2013187","journal-title":"Clinicoecon Outcomes Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06900-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06900-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06900-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:06:24Z","timestamp":1778756784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06900-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["6900"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06900-w","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.B. serves as the Editor-in-Chief of Annals of Hematology. F.E. has consultancy or advisory role for AbbVie, Incyte, Novartis, FibroGen, GlaxoSmithKline (GSK), and Jazz Pharmaceuticals, and has received research grant (institution) from Daiichi Sankyo and Otsuka, all outside the submitted work. A.V. reports grants or contracts from Jazz Pharmaceuticals, AstraZeneca, and AbbVie. A.V. has received consulting fees from Jazz Pharmaceuticals, AbbVie, Servier, Istituto Gentili, Bristol Myers Squibb, Pfizer, Astellas, Otsuka, Janssen, and Daiichi Sankyo. A.V. has also received honoraria from Servier, Jazz Pharmaceuticals, AbbVie, Otsuka, Pfizer, Astellas, Astex, and Janssen, and support for attending meetings and\/or travel from Servier, Janssen, AbbVie, Daiichi Sankyo, and Pfizer, all outside the submitted work. F.E., M.L., and A.V. are authors of some of the studies included in this review. The authors declare that they have no other relevant financial or non-financial interests related to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"249"}}